Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
chemotherapy
Biotech
OSE shares 65% OS rate behind cancer vaccine's phase 2 win
OSE shared survival data behind its therapeutic vaccine’s pancreatic cancer win, backing up “pipeline in a product” claims.
James Waldron
Jun 3, 2025 7:05am
Corcept's phase 3 cancer win sends stock skyrocketing 85%
Mar 31, 2025 10:25am
Boston Scientific to buy chemo pump implant for liver tumors
Nov 25, 2024 12:00pm
Approved IBS drug may help overcome prostate cancer resistance
Jan 22, 2024 11:00am
Chemo drug boosts Daiichi Sankyo ADC in prostate cancer models
Nov 16, 2023 7:35am
Cancer pill works like a snowstorm shutting down an airport
Aug 1, 2023 11:45am
